Wednesday, 30 March 2011

Dr Reddy’s buys GSK’s US penicillin manufacturing facility



Dr Reddy’s Laboratories today said it has acquired GlaxoSmithKline’s US penicillin manufacturing facility and the rights to the Augmentin and Amoxil brands in the United States for an undisclosed sum.

“GSK will retain the existing rights of these brands outside the United States,” Dr Reddy’s said in a filing to the Bombay Stock Exchange (BSE).

The acquisition of the oral penicillin manufacturing facility in Bristol and product portfolio was completed yesterday and is pursuant to the agreement signed by the companies on November 23, 2010, it added.

The company, however, did not disclose the financial terms and conditions of the transaction.

Brands Augmentin and Amoxil, which are used for treating bacterial infections, are trademarks of GlaxoSmithKline.

Shares of Dr Reddy’s were being quoted at Rs 1,628.50 apiece in afternoon trade on the BSE today, up 2.21 per cent from their previous close.

(Source from: businessline)

No comments:

Post a Comment

Disclaimer


* Use of the information and data contained within this Site or these pages is at your sole risk.
* If you rely on the information on this Site you are responsible for ensuring by independent verification its accuracy, currency or completeness.
* This Site includes links to other web sites operated by the Government and private parties.
* These linked web sites will have their own terms and conditions of use and you should familiarize yourself with these.